Kidney Cancer clinical trials in Rhode Island

10 actively recruiting kidney cancer trials at 2 sites across Rhode Island.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 2, Phase 3 Recruiting NIH

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05987241

Sites in Rhode Island:

Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, su…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT06661720

Sites in Rhode Island:

Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…

Sponsor: Children's Oncology Group

NCT ID: NCT04322318

Sites in Rhode Island:

Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…

Sponsor: Regeneron Pharmaceuticals

NCT ID: NCT03972657

Sites in Rhode Island:

Lifespan Cancer Institute — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the P…

Sponsor: 7 Hills Pharma, LLC

NCT ID: NCT06362369

Sites in Rhode Island:

Brown University Health Cancer Institute — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JAN…

Sponsor: Janux Therapeutics

NCT ID: NCT05783622

Sites in Rhode Island:

Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBVCLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (T…

Sponsor: Calico Life Sciences LLC

NCT ID: NCT04777994

Sites in Rhode Island:

Lifespan Cancer Institute at Rhode Island Hospital /ID# 225705 — Providence, Rhode Island

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Rhode Island:

Providence Veterans Administration Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Recruiting Network

Project: Every Child for Younger Patients With Cancer

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…

Sponsor: Children's Oncology Group

NCT ID: NCT02402244

Sites in Rhode Island:

Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Rhode Island:

Massive Bio SYNERGY-AI site — Providence, Rhode Island

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20